Marksans Pharma Share Price

Marksans Pharma Share Price

NSE: MARKSANS
|
Pharmaceuticals

₹ 317.25

+₹0.85 (0.27%)
1D
Last updated 13 Oct, 2026, 15:57 IST

Marksans Pharma Share Price Today

As of 14 Oct 2026, Marksans Pharma share price is ₹317.25. The stock opened at ₹316.95, compared to its previous close of ₹316.40. During today's trading session, Marksans Pharma share price moved in the range of ₹309.80 to ₹318.00, with an average price of ₹313.90 for the day. Looking at its last 52-week, the stock has touched a low of ₹155.00 and a high of ₹350.95. On the performance front, Marksans Pharma share price has increased by 80.11% over the last six months and is up 78.32% on a year-on-year basis.

₹309.80
0.27% up today
₹318.00
1D LOW
1D HIGH

Marksans Pharma Returns Calculator

Volume
10,11,092
Average traded price
₹313.80
Last traded time
03:57:24 13 Oct
Last traded quantity
50
Circuit
L
H
₹253.80
₹380.70
52-week
L
H
₹155.00
₹350.95
Mkt Cap Cr
14,317.71
P/E
27.47
P/B
4.74
ROA
13.5%
ROE
13.82%
ROCE
17.37%
Quick Ratio
3.32
EV/EBITDA
16.37
Based on fundamentals, this stock's
Step 4 of 5
Performance
Good
Marksans Pharma outperforming most market indices
Step 1 of 5
Valuation
Overvalued
Marksans Pharma appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Marksans Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,067.0134.835.0511.19%13.74%17.33%2.3121.42
Divis Laboratories2,48,982.9885.1214.8514.6%15.32%19.56%3.556.28
Torrent Pharmaceuticals1,76,300.5082.5521.164.87%25.49%13.85%0.7538.11
Zydus Lifesciences1,13,615.6924.744.198.57%18.59%17.35%0.9114.87
Laurus Labs1,11,898.66102.6321.1110.38%16.77%16.14%0.6853.86
Cipla1,06,129.9631.623.087.92%11.27%14.95%2.517.83
Dr. Reddy's Laboratories1,02,707.4132.262.75.48%11.07%12.54%1.3515.86
Mankind Pharma99,089.5247.926.087.36%11.74%13.13%0.7425.7
Aurobindo Pharma97,972.4726.42.596.34%9.25%11.76%1.1512.47
Lupin89,628.8316.033.9614.47%23.76%24.88%1.429.56

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About Marksans Pharma

Marksans Pharma Share Price
ISIN
INE750C01026
Sector Market Cap
₹ 14,317.71 Cr

Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.

The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.

Business operations

Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.

In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.

Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.

Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.

The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.

Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.

In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.

Marksans Pharma Financial Highlights

  • Revenue: Marksans Pharma reported revenue of ₹3,033.47 crore in FY26 vs ₹2,689.18 crore in FY25. It showed an increase of 12.80% on a yearly basis.
  • Operating Profit: Marksans Pharma reported an operating profit of ₹560.56 crore in FY26 vs ₹503.97 crore in FY25. It showed an increase of 11.23% on a year-on-year basis.
  • Net Profit: Marksans Pharma reported a net profit of ₹420.06 crore in FY26 vs ₹382.62 crore in FY25. It showed an increase of 9.79% on a yearly basis.

Marksans Pharma Quarterly Result Highlights

  • Marksans Pharma reported revenue of ₹866.20 crore in Jun 2026, compared with ₹891.28 crore in Mar 2026, representing a decrease of 2.81% on a quarter-on-quarter (QoQ) basis.
  • Marksans Pharma reported an operating profit of ₹206.57 crore in Jun 2026, compared with ₹200.00 crore in Mar 2026, representing an increase of 3.28% on a quarter-on-quarter (QoQ) basis.
  • Marksans Pharma reported a profit of ₹159.41 crore in Jun 2026, compared with ₹149.03 crore in Mar 2026, reflecting an increase of 6.97% on a QoQ basis.
  • The earnings per share (EPS) of Marksans Pharma stood at ₹9.22 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
43.87%
FII
17.47%
Other DII
1.83%
Retail and other
32.47%
Mutual funds
4.36%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 202516.92%
Dec 20258.12%
Mar 202616.76%
Jun 202617.47%
1 day
+0.27%
1 week
-2.20%
1 month
-3.69%
1 year
+78.32%
3 years
+185.04%
5 years
+354.19%
Day
Open / Close
Change %
13 Oct 26
₹316.95 / ₹317.25
+0.27%
12 Oct 26
₹310.00 / ₹316.40
+2.36%
09 Oct 26
₹308.50 / ₹309.10
+0.42%
08 Oct 26
₹326.10 / ₹307.80
-5.42%
Show more

Marksans Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,950.94₹2,622.85₹2,177.41₹1,852.14
Other Income₹82.53₹66.33₹50.42₹59.31
Total Revenue₹3,033.47₹2,689.17₹2,227.83₹1,911.45
Total Expenses₹2,472.92₹2,185.21₹1,804.30₹1,573.80
Profit Before Tax₹560.56₹503.97₹423.53₹337.65
Tax₹140.49₹121.35₹108.63₹72.33
Profit After Tax₹420.06₹382.62₹314.90₹265.32
EPS - Basic₹9.22₹8.40₹6.92₹6.41
EPS - Diluted₹9.22₹8.40₹6.92₹6.41

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹560.56₹503.97₹423.53₹337.65
Income before WC changes₹660.24₹573.34₹478.95₹411.89
Change in Assets-₹71.06-₹290.68-₹178.88-₹94.69
Change in Liabilities₹8.60₹49.91₹52.69-₹16.78
Change in WC-₹62.46-₹240.77-₹126.19-₹111.47
Cash flow from Operations₹458.13₹206.66₹230.41₹237.41
Cash flow from Investing-₹248.27-₹49.01-₹140.84-₹259.21
Cash flow from Financing-₹70.93-₹65.15-₹68.73₹197.83
Total Cash Flow₹138.93₹92.51₹20.84₹176.03
Cash (Start of the year)₹495.79₹403.28₹382.44₹206.41
Cash (End of the year)₹634.14₹495.79₹403.28₹382.44

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹1,138.16₹1,035.51₹818.46₹515.09
Current Assets₹2,722.74₹2,204.12₹1,862.49₹1,675.30
Total Assets₹3,860.90₹3,239.63₹2,680.95₹2,190.39
Current Liabilities₹527.09₹477.34₹389.85₹340.99
Net Current Asset₹2,195.65₹1,726.78₹1,472.64₹1,334.31
Non-Current Liabilities₹281.13₹272.91₹205.20₹84.33
Equity Capital₹3,052.68₹2,489.38₹2,085.91₹1,765.07
Total Equity & Liabilities₹3,860.90₹3,239.63₹2,680.95₹2,190.39

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,341.48₹1,174.37₹853.27₹655.20
Other Income₹103.53₹65.79₹62.07₹60.48
Total Revenue₹1,445.01₹1,240.16₹915.35₹715.69
Total Expenses₹1,053.47₹996.90₹743.45₹583.65
Profit Before Tax₹391.54₹243.26₹171.89₹132.04
Tax₹90.85₹54.99₹38.13₹29.17
Profit After Tax₹300.70₹188.27₹133.76₹102.87
EPS - Basic₹6.64₹4.15₹2.95₹2.48
EPS - Diluted₹6.63₹4.15₹2.95₹2.48

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹391.54₹243.26₹171.89₹132.04
Income before WC changes₹366.88₹235.67₹155.50₹142.94
Change in Assets-₹37.56-₹212.02-₹145.87-₹116.44
Change in Liabilities-₹45.23₹53.91₹63.19₹56.84
Change in WC-₹82.79-₹158.11-₹82.68-₹59.60
Cash flow from Operations₹211.09₹31.02₹34.05₹51.73
Cash flow from Investing-₹140.29₹17.24-₹114.22-₹194.62
Cash flow from Financing-₹39.23-₹29.92-₹26.22₹210.02
Total Cash Flow₹31.56₹18.34-₹106.38₹67.12
Cash (Start of the year)₹60.27₹41.93₹148.31₹81.19
Cash (End of the year)₹91.25₹60.27₹41.93₹148.31

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹684.95₹673.08₹568.33₹431.10
Current Assets₹1,309.08₹1,082.22₹947.70₹913.76
Total Assets₹1,994.03₹1,755.30₹1,516.04₹1,344.86
Current Liabilities₹310.25₹345.64₹272.44₹216.54
Net Current Asset₹998.83₹736.59₹675.27₹697.22
Non-Current Liabilities₹31.47₹26.18₹20.90₹17.00
Equity Capital₹1,652.31₹1,383.49₹1,222.71₹1,111.32
Total Equity & Liabilities₹1,994.03₹1,755.30₹1,516.04₹1,344.86
* All values are in INR Crore
Qty
Bid
234
317.25
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 234
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
47.11
Neutral
ATR (14)
14.02
Neutral
STOCH(9,6)
30.88
Neutral
STOCH RSI (14)
23
Neutral
ADX(9)
18.33
Bullish
UO(9)
41.91
Neutral
ROC(12)
-5.97
Bearish
WillR(14)
-72.47
Neutral
Period
Simple value
Exponential vaue
5D
315.2
316.95
10D
322.27
320.51
20D
325.82
323.15
50D
318.27
312.95
100D
286.45
287.06
Volume trend — traded volume by day
13 Oct10L
12 Oct8L
9 Oct11L
8 Oct23L
7 Oct21L
Average14L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Marksans Pharma Share Price
Marksans Pharma
Pharmaceuticals
Add Stock
Add Another

Marksans Pharma Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.